Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
- Dwight D. Eplin1, *, Anna D. Jackson1, Austin M. Smith1, Brent Salvig1, Wichai Chinratanalab1, 2, Bipin N. Savani1, 21 VA Tennessee Valley Healthcare System; Nashville, Tennessee2 Vanderbilt University Medical Center; Nashville, Tennessee*Corresponding author. Postal address: VA Tennessee Valley Healthcare System, 1310 24th Avenue South (119), Nashville, TN 37212. Tel.: +1-615-873-6386. Email: Dwight.Eplin@va.gov
- Corresponding Author
- Dwight D. Eplin
- https://doi.org/10.2991/chi.d.191008.001How to use a DOI?
- Hematopoietic stem cell transplantation, Biosimilar, Granulocyte colony-stimulating factor, Stem cell mobilization, Filgrastim, Tbo-filgrastim
The biologic medication filgrastim is approved by the Food and Drug Administration (FDA) to mobilize hematopoietic progenitor cells (HPCs) for collection by leukapheresis for autologous hematopoietic stem cell transplant (HSCT). The FDA-approved biologic tbo-filgrastim is currently used off-label for this indication in both autologous and allogeneic HSCT at the Tennessee Valley Healthcare System. The purpose of this review is to compare the efficacy of filgrastim and tbo-filgrastim for this indication. The primary outcomes were the proportion of autologous patients and allogeneic donors with a CD34+ count ≥15 × 103 cells/uL on day 4 of filgrastim or tbo-filgrastim mobilization. The secondary outcome was the use of plerixafor in the autologous population. A total of 469 subjects were identified for inclusion; 367 underwent mobilization for autologous HSCT and 102 for allogeneic HSCT donation. The primary outcome was achieved in 47.5% of patients who received filgrastim compared to 50.2% who received tbo-filgrastim in the autologous population (p = 0.67). Among donors for allogeneic HSCT, there was no difference between those eligible for collection on day 4 of filgrastim or tbo-filgrastim administration (97.6% vs. 100%, p = 0.41). No significant difference was identified in the number of patients requiring plerixafor use in the autologous HSCT population. The use of the biosimilar tbo-filgrastim for mobilization in either autologous HSCT patients or allogeneic HSCT donors has comparable outcomes to that of the biotherapeutic reference product filgrastim at a reduced cost to the healthcare system.
- © 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Cite this article
TY - JOUR AU - Dwight D. Eplin AU - Anna D. Jackson AU - Austin M. Smith AU - Brent Salvig AU - Wichai Chinratanalab AU - Bipin N. Savani PY - 2019 DA - 2019/10 TI - Use of Biosimilar Granulocyte Colony-Stimulating Factor for Mobilization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation JO - Clinical Hematology International SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.191008.001 DO - https://doi.org/10.2991/chi.d.191008.001 ID - Eplin2019 ER -